

# Strengthening data driven drug discovery research - LEO Pharma partners with grit42

*LEO Pharma A/S selects grit42 as its strategic partner in a new initiative to promote data driven drug discovery research.*

COPENHAGEN, DENMARK, October 12, 2017 /EINPresswire.com/ -- [LEO Pharma](#) helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO

Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma has recently initiated a strategic initiative aiming to transform data management and informatics for the research organization. The transformation will promote innovation, enhance efficiency and increase the confidence in decisions throughout research, resulting in more innovative products brought faster to the patients. The collaboration with [grit42](#) will enable this transformation.

“

We see a great potential in applying state-of-the-art data management to leverage our R&D and improve our decision making. To strengthen these capabilities, we selected grit42 as our strategic partner”

*Thorsten Thormann, Vice President of Research at LEO Pharma*



LEO Pharma selects grit42 as its strategic partner in a new initiative to promote data driven drug discovery research.

"We see a great potential in applying state-of-the-art data management and data integration to leverage our R&D activities and improve our decision making. To strengthen these capabilities, we selected grit42 as our strategic software partner after a thorough evaluation against various competing solutions and we are excited about the impact that this collaboration can offer." states Thorsten Thormann, Vice President of Research at LEO Pharma.

"Through 15 years of anthropological observations in pre-clinical drug discovery labs, we literally understand the

specific workflows that our customers do, which in turn enables us to make the ideal software to support them", states CEO of grit42, Claus Stie Kallesøe, and continues, "Now signing up to be a strategic partner with LEO Pharma validates our approach, and we look forward to rolling out our software across all the different phases of the drug discovery process, from in vitro and in vivo, to ADME and safety toxicology."

Copenhagen-based grit42 focuses on research and lab informatics software for pre-clinical drug discovery. After having worked together for 15 years as the internal research informatics department at a Danish pharmaceutical company, grit42 launched in 2014. Read more at <http://www.grit42.com>

Contact LEO Pharma  
Thorsten Thormann  
Vice President Research  
\_tthdk@leo-pharma.com  
TEL: +45 7226 2457

Contact grit42  
Lasse Görlitz  
Head of Branding  
goerlitz@grit42.com  
TEL: +45 2758 2601

Lasse Goerlitz  
grit42  
+45 2758 2601  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.  
© 1995-2017 IPD Group, Inc. All Right Reserved.